Dendreon

February 5, 2012

2011 Review and Outlook for Biotechnology in 2012

January 25, 2012 By MD Becker Partners Leave a Comment

2012

Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers

Filed Under: Articles Tagged With: 2011, 2012, Access to Capital, Akorn, AKRX, BDSI, BioDelivery Sciences, biotechnology, BMY, Bristol-Myers Squibb, Canaan Partners, consolidation, defensive sector, Dendreon, DNDN, Economic Driver, Endo Pharmaceuticals, ENDP, FDA, Flagship Ventures, HGSI, Human Genome Sciences, Inc., Inhibitex, INHX, ISTA, ISTA Pharmaceuticals, M&A, MDVN, Medivation, NASDAQ, New Drug Approvals, outlook, PhRMA, Pipeline, Review, RHHBY, roche, Valeant Pharmaceuticals, Vivo Ventures, VRX, Xenon Pharmaceuticals

2012 Preview: Cancer Immunotherapy Catalysts

December 14, 2011 By MD Becker Partners 1 Comment

MD Becker Partners' Life Science Digest: 2012 graphic

2012 represents a period with robust news flow for emerging immuno-oncology companies

Filed Under: Articles Tagged With: AE37, AGEN, Agenus, Allovectin, Amgen, AMGN, Antigen Express, BAVA, Bavarian Nordic, BMY, Bristol-Myers Squibb, cancer vaccine, castrate-resistant prostate cancer, CELG, Celgene, Celldex Therapeutics, CLDX, cv-301, Dendreon, DNDN, Generex, GlaxoSmithKline, GlobeImmune, GNBT, gp100, GSK, HyperAcute, Idera Pharmaceuticals, IDRA, immunotherapy, IMO-2055, ipilimumab, Jennerex, JX-594, MAGE-A3, melanoma, NewLink Genetics, NLNK, NSCLC, Oncothyreon, OncoVex, ONTY, pancreatic cancer, panvac, PROSTVAC, Provenge, QS-21, sipuleucel-T, Stimuvax, TG4010, transgene, Vical, VICL, Yervoy

Ipilimumab Approval Highlights Immunotherapy Renaissance

March 25, 2011 By MD Becker Partners Leave a Comment

mab_slide

On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.

Filed Under: Articles Tagged With: AGEN, Agenus, Allovectin-7, Amgen, AMGN, Antigenics, AVAX, AVAX Technologies, AVXT.PK, Bavarian Nordic, BIIB, Biogen Idec, BiovaxID, Biovest International, BioVex, BMY, Bristol-Myers Squibb, BVTI, CancerVax, Canvaxin, CDX-110, Celldex Therapeutics, CLDX, Corixa, Dendreon, DNDN, GlaxoSmithKline plc, GMK vaccine, GSK, ipilimumab, Lucanix, MAGE-A3 ASCI, Melacine, MVAX, Novarx, Oncophage, Oncothyreon, OncoVex, ONTY, Oxford BioMedica, PGNX, Progenics Pharmaceuticals, PROSTVAC, Rituxan, rituximab, Stimuvax, TG4010, transgene, Trovax, Vical, VICL, William Coley, Yervoy

To Partner, or Not to Partner: That is the Question

March 10, 2011 By MD Becker Partners 2 Comments

MD Becker Partners' Life Science Digest: To Partner, or Not to Partner - That is the Question

Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]

Filed Under: Articles Tagged With: Allos Therapeutics, ALTH, Amgen, AMGN, Aranesp, AVAX Technologies, BAVA.CO, Bavarian Nordic, biotechnology, Biovest International, BMY, Bristol-Myers Squibb, BVTI, CELG, Celgene, Cell Therapeutics, Celldex Therapeutics, Charles Duncan, CLDX, CTIC, CYCC, Cyclacel Pharmaceuticals, David Sable, Dendreon, DNDN, Eli Lilly, Epogen, Erbitux, EXEL, Exelixis, Folotyn, hpv, ipilimumab, JMP Securities, JNJ, Johnson & Johnson, lenalidomide, Light Sciences Oncology, LLY, MDVN, Medarex, Medivation, OGXI, OncoGenex, Oncolytics Biotech, Oncothyreon, ONCY, ONT-10, ONTY, PFE, Pfizer, pralatrexate, Procrit, Revlimid, roche, SNSS, Sol Barer, Special Situations Fund, Stimuvax, Sunesis Pharmaceuticals, transgene, Yervoy, ZymoGenetics

2010 Cancer Immunotherapy: A Long-Awaited Reality

October 28, 2010 By MD Becker Partners Leave a Comment

Cancer Immunotherapy: A Long-Awaited Reality conference, October 21, 2010

Selected photos from Cancer Immunotherapy: A Long-Awaited Reality conference hosted by MD Becker Partners and BioBusiness.TV held at the New York Academy of Medicine on October 21, 2010 (Note: Click on photo to enlarge). Alternatively, click here to view a video montage of the conference photos.

Filed Under: Photo Galleries Tagged With: A Long-Awaited Reality Conference, BioBusiness.TV, biotechnology, cancer immunotherapy, Dendreon, DNDN, MD Becker Partners, Michael Becker, New York, New York Academy of Medicine